Medical Device Reimbursement: ReGARDD Forum Notes

Perspectives on Medical Reimbursement By JR Associates What should medical device researchers know about premarket FDA submissions? And what should they understand about reimbursement in early stages of product development?  These core questions inspired the first educational seminar hosted by ReGARDD (Regulatory Guidance for Academic Research of Drugs and Devices) in April 2017, where our…

Read More »

Medical Device Innovation and Reimbursement: MDMA 2016 Conference Notes

Read notes from MDMA Reimbursement Conference presentations 2016

Perspectives on Medical Reimbursement By JR Associates Through the years, our consultants have become popular as featured speakers at a variety of prestigious medical technology forums. But the highlight of our annual events calendar is always the MDMA Coverage, Reimbursement & Health Policy Conference. It is deeply rewarding to connect directly with medical device professionals and discuss critical…

Read More »

MDMA Reimbursement Conference Notes: 2015

Perspectives on Medical Reimbursement By JR Associates (Editor’s Note: Our leaders spoke again at the 2016 MDMA Reimbursement Conference on November 16-17 in Baltimore. As always, it was rewarding to reconnect with medical device professionals and explore timely reimbursement issues. We’ll be recapping those sessions on the blog before the end of December. ) For years, our consultants…

Read More »

Medical Device Coverage: Do Private Payers Follow Medicare’s Lead?

Perspectives on Medical Reimbursement By JR Associates When making decisions about medical device coverage, do private insurers take their cues from Medicare (CMS)? Not necessarily, according to a recent study published in the peer-review journal, Health Affairs. According to the research abstract, an analysis of CMS national coverage decisions (NCDs) revealed that: ~50% were equivalent to corresponding private payer policies ~25% were…

Read More »

What Should Life Sciences Startups Know About Reimbursement?

Reimbursement for Life Sciences Startups - JR Assocates VP Global Health Policy Jo Ellen Surzberg at Harvard Innovation Lab

Perspectives on Medical Reimbursement By JR Associates “Will my device be reimbursed?” This is one of the most important questions life sciences entrepreneurs must consider when developing new medical technology. But in today’s dynamic and complex healthcare environment, clear answers can be elusive. Harvard Innovation Lab recently invited our VP of Global Health Policy, Jo Ellen Slurzberg, to help clarify…

Read More »

How Can Medical Innovators Build a Case for Reimbursement?

Perspectives on Medical Reimbursement By JR Associates Coverage. Coding. Payment. These three factors deeply influence reimbursement for every new medical technology product. But there are no “cookie cutter” solutions. Because the reimbursement landscape is so complex and time consuming, it’s smart to start preparing for reimbursement as early as possible in the business planning and product development process. But…

Read More »

Autism Investment Conference Session Notes

Jo Ellen Slurzberg_Reimbursement Strategies Autism Investment Conference

Perspectives on Medical Reimbursement By JR Associates Continuing its efforts to cultivate a marketplace of innovation that better serves those affected by autism, Autism Speaks recently hosted its third annual Autism Investment Conference in Boston. Our VP of Global Health Policy, Jo Ellen Slurzberg, was among the nearly 200 investors, entrepreneurs, healthcare advocates and corporate…

Read More »

Proposed Changes In MPFS IDE Clinical Trial Coverage Rule: Comments to CMS

Perspectives on Medicare Policies By JR Associates SUBJECT: Medicare Physician Fee Schedule Rule: Proposed Changes for the Process for Covering Items and Services in an Investigational Device Exemption (IDE), Centers for Medicare and Medicaid Services (CMS) 78 Fed. Reg. 43282, 43342-47, 43523-25 (July 19, 2013) OVERVIEW: JR Associates is concerned about CMS’ proposed changes to…

Read More »